Oral Bisphosphonates and Improved Survival of Breast Cancer
Gad Rennert(Technion – Israel Institute of Technology), Hedy S. Rennert(Technion – Israel Institute of Technology), Keren Landsman(Carmel Medical Center), Walid Saliba(Technion – Israel Institute of Technology), Naomi Gronich(Carmel Medical Center), Mila Pinchev(Michigan Medicine), Hadassah Goldberg(Bar-Ilan University), Arie Bitterman(Carmel Medical Center), Mariana Steiner(Sheba Medical Center), Georgeta Fried(Roche (Switzerland)), Idit Lavi(Carmel Medical Center), Anath Flugelman(Carmel Medical Center)
Cited by 48
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
|Nature Genetics|2017|804
Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study
|PLoS ONE|2017|668
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634